FDA Approves First-Ever Agent to Delay Type 1 Diabetes Onset FDA Approves First-Ever Agent to Delay Type 1 Diabetes Onset

Teplizumab delayed progression to clinical type 1 diabetes by about 2 years compared with placebo in individuals destined to develop the condition because of autoantibody levels.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news